Bangalore 16th September 2010
To help accelerate the drug discovery process
Biocon, India's largest biotechnology company, entered into an agreement with Teleradiology Solutions, a pioneer of the domain in India, to provide teleradiology reporting services to Clinigene, Biocon's Clinical Research Organization. Teleradiology Solution's quality-driven reporting process and cutting-edge technology platform have the potential to greatly benefit biotech and pharma companies, obviating delays in the completion of clinical trials by optimizing the radiology reporting process.
Clinical trials radiology is a unique class by itself. In clinical trials, the objective is to demonstrate formally the efficacy, safety and cost utility of a new therapy for regulatory approval, with the fewest patients and in the shortest time possible. Teleradiology Solutions offers pharmaceutical vendors, clinical research organizations, and biotechnology organizations the opportunity to shorten their development cycles by using TRS Clinical Trials Radiology Reporting service. The organisation offers quality reporting by radiologists experienced in RECIST (Response Evaluation Criteria In Solid Tumors) and WHO (World Health Organisation) measurement criteria.
According to Kiran Mazumdar-Shaw, Chairman & Managing Director of Biocon Ltd, "To achieve our main objective, Accelerating Clinical Research, we leverage on an adept mix of technology, experience and personal traits. Keeping in line with our mission, Teleradiology Solutions, given their impressive track record, was the partner of choice to meet our complex image analysis requirements. The signing of this agreement further endorses Bangalore as the hub of excellence, both in Biotechnology as well as in high end healthcare delivery to the world."
According to Dr Arjun Kalyanpur, MD and Chief Radiologists, Teleradiology Solutions, "For pharmaceutical and Biotechnology companies involved in drug development R&D, delays in the drug development cycle can be an issue of concern. These are in part related to delays in reporting of radiologic scans that are performed to confirm that the patient under treatment has responded positively to the drug being evaluated in the clinical trial. The delays are in turn related to the worldwide shortage of radiologists, estimated to be as high as 20% in some studies. We are happy to partner with Biocon and offer our services to ensure timely execution and quality evaluation for clinical trials in radiology."
Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon's value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMEA acceptance. Biocon's robust product offering includes the world's first Pichia-based recombinant human insulin, INSUGEN(R) and India's first indigenously produced monoclonal antibody BIOMAb-EGFR(TM).
About Teleradiology Solutions
Teleradiology Solutions (TRS) was founded in 2002 by Dr. Arjun Kalyanpur and Dr. Sunita Maheshwari. It was initially set up to provide hospitals in the United States with night shift radiology solutions and now provides teleradiology to hospitals in Singapore and India with other countries on the anvil. Teleradiology Solutions (US) is accredited by the US Joint Commission of Accreditation of Healthcare Organizations (JCAHO). It is also the first organization outside Singapore to be accredited by the Ministry of Health, Singapore.
The company provides teleradiology services to hospitals around the globe, which includes interpretation of all non-invasive imaging studies, namely CT, MRI, ultrasound, nuclear medicine studies and digitized Xrays. The company provides subspecialty consultations in cardiovascular and oncologic imaging to hospitals in India as well, and has joint research partnerships with major technology vendors such as GE, to explore new techniques in 3D imaging analysis.